182618-86-6

Basic information

• Product Name: 4-(4-NITROPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: TERT-BUTYL 4-(4-NITROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;4-(4-NITROPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-4-(4-NITROPHENYL)-PIPERAZINE;4-(4-Nitrophenyl)piperazine-1-carboxylicacidtert-butylester95%;4-(4-NITROPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER 95%;t-Butyl 4-(4-nitrophenyl)piperazine-1-carboxylate;tert-Butyl 4-(4-nitrophenyl)piperazine-1-carboxylate;ert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate
• CAS NO: 182618-86-6
• Molecular Formula: C₁₅H₂₁N₃O₄
• Molecular Weight: 307.34
• Product Categories: API intermediates
• Mol File: 182618-86-6.mol
• Article Data: 57

Chemical Properties

• Boiling Point: 456.6 °C at 760 mmHg
• Flash Point: 229.9 °C
• Appearance: /Solid
• Density: 1.22 g/cm³
• Vapor Pressure: 1.6E-08mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(4-NITROPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-NITROPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(182618-86-6)
• EPA Substance Registry System: 4-(4-NITROPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(182618-86-6)

Safety Data

• Hazardous Substances Data: 182618-86-6(Hazardous Substances Data)

Usage

General Description

4-(4-Nitrophenyl)piperazine-1-carboxylic acid tert-butyl ester is a chemical compound that belongs to the class of piperazine compounds. It is a derivative of piperazine and contains a nitrophenyl group and a tert-butyl ester group. 4-(4-NITROPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER has potential applications in pharmaceutical research and drug development due to its ability to modify the activity of certain biological pathways. It is often used as a precursor in the synthesis of various pharmaceuticals and can also be used as a tool compound in biochemical and pharmacological studies. Additionally, it is important to note that this compound should be handled and stored in accordance with proper safety and regulatory guidelines due to its potential hazards.

InChI:InChI=1/C15H21N3O4/c1-15(2,3)22-14(19)17-10-8-16(9-11-17)12-4-6-13(7-5-12)18(20)21/h4-7H,8-11H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 6269-89-2 1-(4-Nitrophenyl)piperazine 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 586-78-7 para-nitrophenyl bromide 
• 100-00-5 4-chlorobenzonitrile 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 260252-87-7 1-(4-nitrophenyl)piperazine hydrochloride 
• 260252-87-7 4-(4'-nitrophenyl)piperazine hydrochloride 
• 352329-10-3 4-{4-[7-(3-Cyclohexyl-ureido)-6-fluoro-pyrido[2,3-d]pyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 170911-92-9 4-(4-aminophenyl)-1-t-butyloxycarbonylpiperazine 
• 193902-64-6 1-t-butoxycarbonyl-4,4'-aminophenylpiperazine hydrochloride 
• 193902-80-6 tert-butyl 4-(2-chloro-4-nitro-phenyl)piperazine-1-carboxylate 
• 1393900-48-5 2-(2-(2-(2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1393900-51-0 2-(2-(2-(2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1393901-18-2 tert-butyl 4-(4-((4-(2-(2-(methylamino)-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1393900-52-1 N-methyl-2-(2-(2-(2-((4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1393901-26-2 tert-butyl 4-(4-((4-((3-oxoisoindolin-4-yl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1393901-28-4 tert-butyl 4-(4-((4-(2-(3-oxoisoindolin-4-yl)ethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1393900-53-2 7-(2-(2-((4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)isoindolin-1-one 
• 1393901-33-1 tert-butyl 4-(4-((4-((3-carbamoyl-4-methylphenyl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1393901-34-2 tert-butyl 4-(4-((4-(3-carbamoyl-4-methylphenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1393900-57-6 2-methyl-5-(2-(2-((4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)benzamide 
• 1393901-53-5 tert-butyl 4-(4-((4-((3-(2-ethoxy-2-oxoethyl)pyrazin-2-yl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperidine-1-carboxylate 

Relevant articles and documents

Synthesis and structure-activity relationships of new 2-phenoxybenzamides with antiplasmodial activity

The 2-phenoxybenzamide 1 from the Medicines for Malaria Venture Malaria Box Project has shown promising multi-stage activity against different strains of P. falciparum. It was successfully synthesized via a retrosynthetic approach. Subsequently, twenty-one new derivatives were prepared and tested for their in vitro activity against blood stages of the NF54 strain of P. falciparum. Several insights into structure-activity relationships were revealed. The antiplasmodial activity and cytotoxicity of compounds strongly depended on the substitution pattern of the anilino partial structure as well as on the size of substituents. The diaryl ether partial structure had further impacts on the activity. Additionally, several physicochemical and pharmacokinetic parameters were calculated (log P, log D7.4 and ligand efficiency) or determined experimentally (passive permeability and CYP3A4 inhibition). The tert-butyl-4-{4-[2-(4-fluorophenoxy)-3-(trifluoromethyl)benzamido]phenyl}piperazine-1-carboxylate possesses high antiplasmodial activity against P. falciparum NF54 (PfNF54 IC50 = 0.2690 μM) and very low cytotoxicity (L-6 cells IC50 = 124.0 μM) resulting in an excellent selectivity index of 460. Compared to the lead structure 1 the antiplasmodial activity was improved as well as the physicochemical and some pharmacokinetic parameters.

Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via in Silico Design

Targeted protein degradation by proteolysis-targeting chimera (PROTAC) is one of the exciting modalities for drug discovery and biological discovery. It is important to select an appropriate linker, an E3 ligase ligand, and a target protein ligand in the

Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket

With our previously identified potent NNRTIs 25a and HBS-11c as leads, series of novel thiophene[3,2-d]pyrimidine and thiophene[2,3-d]pyrimidine derivatives were designed via molecular hybridization strategy. All the target compounds were evaluated for their anti-HIV-1 activity and cytotoxicity in MT-4 cells. Compounds 16a1 and 16b1 turned out to be the most potent inhibitors against WT and mutant HIV-1 strains (L100I, K103N, and E138K), with EC50 values ranging from 0.007 μM to 0.043 μM. Gratifyingly, 16b1 exhibited significantly reduced cytotoxicity (CC50 > 217.5 μM) and improved water solubility (S = 49.3 μg/mL at pH 7.0) compared to the lead 25a (S 50 = 2.30 μM). Moreover, molecular docking was also conducted to rationalize the structure-activity relationships of these novel derivatives and to understand their key interactions with the binding pocket.